BLEEDING-RELATED EPISODES (BRE) IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP) RECEIVING ELTROMBOPAG (EPAG) OR ROMIPLOSTIM (ROMI)- REAL WORLD EVIDENCE FROM 26 US INSTITUTIONS
Author(s)
Forsythe A1, Roy A2, Bhor M2, Socorro O Portella M2
1Purple Squirrel Economics, New York, NY, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
OBJECTIVES: To examine burden of BREs in ITP patients treated with EPAG or ROMI. METHODS: We investigated BREs, a complication of ITP that leads to significant morbidity and mortality, using a syndicated electronic medical records network that contains records for inpatient and outpatient services and procedures, diagnoses, adverse events (AEs), prescriptions and labs for >27 million patients from 26 US hospital institutions. Adult patients diagnosed with primary ITP and treated with EPAG or ROMI with prior steroid treatment were included. Patients with secondary ITP, history of HBV, HCV, HIV, malignancy, severe aplastic anemia, myelodysplastic syndrome, myelofibrosis and splenectomy were excluded. BREs were identified based on bleeding codes [BE] and/or uses of rescue therapy [RES] (intravenous (IV) immunoglobulin administration, IV steroid administration, or platelet transfusion (PT) using a combination of diagnosis, procedure, and medication codes. BREs requiring PT were considered severe (sBRE). BREs after initiation of EPAG or ROMI were compared using Z-tests (two-tailed α=0.05). RESULTS: CONCLUSIONS: This retrospective RWE study emphasizes the significant burden of BREs in ITP patients despite treatment which aims to prevent these episodes. BRE rates identified as BE after controlling for confounding, were significantly higher in ROMI-treated patients as compared to EPAG-treated patients.
Conference/Value in Health Info
2017-11, ISPOR Europe 2017, Glasgow, Scotland
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PSY8
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Systemic Disorders/Conditions